← Back to Search

Gene Therapy

OAV101 for SMA (STRENGTH Trial)

Phase 3
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
SMA diagnosis
Aged 2 to 12 years
Must not have
Contraindications for lumbar puncture procedure
At Baseline, participants are excluded if they received nusinersen (Spinraza®) or risdiplam (Evrysdi®) within a defined timeframe
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 52 weeks
Awards & highlights
Pivotal Trial
No Placebo-Only Group

Summary

This trial tests a gene therapy given as an injection into the lower back in children who haven't used certain other treatments. The therapy works by using a virus to deliver a healthy gene to their cells.

Who is the study for?
This trial is for children aged 2 to 12 with Spinal Muscular Atrophy (SMA) who have previously been treated with nusinersen or risdiplam but stopped. They must show SMA symptoms and not have high antibody levels against AAV9, significant test abnormalities, contraindications for spinal taps, recent vaccinations, hospitalizations for pulmonary events or surgeries planned.
What is being tested?
The study tests OAV101's safety and effectiveness in treating SMA when given through a spinal injection. It involves one treatment day followed by a year of follow-up. Participants are divided into two age groups: 2-5 years old and 6-12 years old.
What are the potential side effects?
Potential side effects aren't specified here but may include reactions related to the immune system due to antibodies against AAV9 or complications from the lumbar puncture procedure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Spinal Muscular Atrophy (SMA).
Select...
I am between 2 and 12 years old.
Select...
I have received at least four doses of Spinraza or been on Evrysdi for 3 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot have a lumbar puncture due to health reasons.
Select...
I have not taken Spinraza or Evrysdi recently.
Select...
I was hospitalized for lung problems or needed nutritional support recently.
Select...
I currently have an infection or a fever.
Select...
I need a machine to help me breathe.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 52 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number and percentage of participants reporting AEs, related AEs, SAEs, and AESIs
Secondary study objectives
Change from baseline to Week 52 visit in Assessment of Caregiver Experience in ACEND instrument score
Change from baseline to Week 52 visit in the HFMSE total score
Change from baseline to Week 52 visit in the RULM total Score

Side effects data

From 2023 Phase 4 trial • 16 Patients • NCT05073133
44%
Pyrexia
44%
Vomiting
31%
Alanine aminotransferase increased
31%
Aspartate aminotransferase increased
31%
Gamma-glutamyltransferase increased
25%
Cough
25%
Platelet count decreased
19%
Bronchiolitis
19%
Influenza
19%
Respiratory tract infection
19%
Hepatic enzyme increased
13%
Bilirubin conjugated increased
13%
Blood lactate dehydrogenase increased
13%
Transaminases increased
13%
Blood alkaline phosphatase increased
13%
Rhinorrhoea
13%
Upper respiratory tract congestion
13%
Gastroenteritis
13%
Irritability
13%
Viral infection
13%
Diarrhoea
13%
Thrombotic microangiopathy
13%
COVID-19
13%
Catarrh
13%
Tonsillitis
6%
Rhinitis
6%
Rash
6%
Coxsackie viral infection
6%
Pneumonia
6%
Constipation
6%
Subcutaneous emphysema
6%
Hepatic failure
6%
Thrombocytopenia
6%
White blood cell count increased
6%
Hypoglycaemia
6%
Upper respiratory tract infection
6%
Nausea
6%
Decreased appetite
6%
Renal failure
6%
Femur fracture
6%
Salivary hypersecretion
6%
Laryngitis
6%
Pneumonia aspiration
6%
Asymptomatic bacteriuria
6%
Hypersensitivity
6%
Pneumonia bacterial
6%
Conjunctivitis
6%
Stomatitis
6%
Urinary tract infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
OAV101A1 1.le 14vg/kg All

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: OAV-101Experimental Treatment1 Intervention
Intrathecal administration of OAV101 at a dose of 1.2 x 10\^14 vector genomes, one time dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
OAV101
2021
Completed Phase 4
~40

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Spinal Muscular Atrophy (SMA) include gene therapy and antisense oligonucleotides. Gene therapy, such as onasemnogene abeparvovec, works by delivering a functional copy of the SMN1 gene to motor neurons, thereby increasing the levels of the essential SMN protein. Antisense oligonucleotides, like nusinersen, modify the splicing of the SMN2 gene to produce more functional SMN protein. These treatments are significant for SMA patients as they address the underlying genetic cause of the disease, leading to potential improvements in motor function and overall survival.

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,921 Previous Clinical Trials
4,254,285 Total Patients Enrolled

Media Library

OAV101 (Gene Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05386680 — Phase 3
Spinal Muscular Atrophy Research Study Groups: OAV-101
Spinal Muscular Atrophy Clinical Trial 2023: OAV101 Highlights & Side Effects. Trial Name: NCT05386680 — Phase 3
OAV101 (Gene Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05386680 — Phase 3
~9 spots leftby Dec 2025